[PubMed] Mller TD, Finan B, Bloom SR, et al
doi:10.3389/fphar.2022.935823
In fact, GLP-1 patients spend about 63% more with med spas and are four times more likely to be new clients
7 As the first approved dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, tirzepatide demonstrated weight loss exceeding 20% in its pivotal trials, establishing a new therapeutic ceiling
Designed with your needs in mind, our alcohol-free spray delivers a transparent protective coating that enhances your skins health and wellbeing
Copper peptide formulations are well suited to this category because they can be combined with hydrating and soothing ingredients that reinforce the skins protective function